Medical News, Journals & Upcoming Events
Most Read Psychiatry Articles on JAMA Network
- Recreational Marijuana Laws and Teen Marijuana Use, 1993-2021 April 24, 2024This cross-sectional study uses data from the Youth Risk Behavior surveys to assess the association of state-level recreational marijuana laws and youth marijuana use.
- Examining Sex Differences in Autism Heritability April 17, 2024This cohort study analyzes sex-specific differences in heritability of autism spectrum disorder among individuals in Sweden.
- Prevalence of Mental Health Disorders Among Individuals Experiencing Homelessness April 17, 2024This systematic review and meta-analysis assesses the prevalence of mental health disorders among people experiencing homelessness.
- Adolescent Media Use and Psychotic Experiences April 10, 2024This cohort study examines data for participants of the Québec Longitudinal Study of Child Development to analyze adolescent trajectories of media use for associations with psychotic experiences during early adulthood.
- A Dynamical Systems View of Psychiatric Disorders—Theory April 3, 2024This narrative review describes a new approach to the diagnosis and treatment of psychiatric disorders that is based on dynamical systems theory, which addresses the concepts of tipping points, cycles, and chaos in complex systems.
JAMA Oncology Current Issue
- Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma April 1, 2024This randomized clinical trial examines if radiotherapy is noninferior to chemoradiotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Broken Promises April 1, 2024At first, the room teems with acquaintances Who you last saw at Thanksgiving Nearly a decade ago
- TMB in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition April 1, 2024This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
- Pertuzumab Plus Trastuzumab Without Chemotherapy for ERBB2-Positive Metastatic Breast Cancer—Reply April 1, 2024In Reply We thank Sun and Wei for raising the important issue of survival with regard to de-escalation of chemotherapy in the presence of highly effective targeted anti-ERBB2 (formerly HER2) therapy. In their comments on our analysis, Sun and Wei conclude that between the time period of 24 to 72 months, reconstructed survival data looking […]
Upcoming Events
To receive information about upcoming events and the latest CE Activities, join our network.